Sorrento Therapeutics Inc.’s filing revealed that its Ji Henry acquired Company’s shares for reported $13999.0 on Jun 14. In the deal valued at $1.40 per share,10,000 shares were bought. As a result of this transaction, Ji Henry now holds 2,065,807 shares worth roughly $ 4.3 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Then, Janda Kim sold 3,000 shares, generating $17,640 in total proceeds. Upon selling the shares at $5.88, the Director now owns 3,000 shares.
Before that, Janda Kim sold 42,357 shares. Sorrento Therapeutics Inc. shares valued at $339,720 were divested by the Director at a price of $8.02 per share. As a result of the transaction, Janda Kim now holds 3,000 shares, worth roughly $6240.0.
Meanwhile, B. Riley Securities initiated its Sorrento Therapeutics Inc. [SRNE] rating to a Buy in a research note published on Tuesday, January 29, 2021; the price target was $26. PT values the company’s stock at a premium of 92.0 to its Tuesday closing price. A number of analysts have revised their coverage, including Alliance Global Partners’s analysts, who began to cover the stock in late January with a ‘”a Buy”‘ rating. H.C. Wainwright also remained covering SRNE and reiterated its “Buy” recommendation on July 31, 2020. Dawson James started covering the stock on May 26, 2020. It rated SRNE as “a Buy”.
Price Performance Review of SRNE
On Tuesday, Sorrento Therapeutics Inc. [NASDAQ:SRNE] saw its stock jump 23.81% to $2.08. On the same session, the stock had its day’s lowest price of $1.73, but rose to a high of $2.21. Over the last five days, the stock has gained 49.64%. Sorrento Therapeutics Inc. shares have fallen nearly -55.27% since the year began. Nevertheless, the stocks have fallen -76.06% over the past one year. While a 52-week high of $11.07 was reached on 01/04/22, a 52-week low of $1.15 was recorded on 05/12/22. SMA at 50 days reached $1.6300, while 200 days put it at $4.1800. A total of 28.37 million shares were traded, compared to the trading of 10.1 million shares in the previous session.
Levels Of Support And Resistance For SRNE Stock
The 24-hour chart illustrates a support level at 1.8000, which if violated will result in even more drops to 1.5300. On the upside, there is a resistance level at 2.2800. A further resistance level may holdings at 2.4900. The Relative Strength Index (RSI) on the 14-day chart is 66.54, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.1300, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 15.12%. Stochastics %K at 75.10% indicates the stock is a holding.
How much short interest is there in Sorrento Therapeutics Inc.?
A steep rise in short interest was recorded in Sorrento Therapeutics Inc. stocks on Apr 28, 2022, growing by 2.27 million shares to a total of 54.66 million shares. Yahoo Finance data shows the prior-month short interest on Mar 30, 2022 was 52.39 million shares. There was a rise of 4.15%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 14.22% of the overall stock float, the days-to-cover ratio (short ratio) rose to 6.37.
Sorrento Therapeutics Inc. [SRNE] – Who Are The Largest Shareholders?
In filings from SSgA Funds Management, Inc., it is revealed that the company now owns 33,960,884 shares, or roughly 8.73% of the outstanding SRNE shares. In other words, the investor’s shares have risen by 19,365,130 from its previous 13-F filing of 14595754.0. Additionally, BlackRock Fund Advisors increased 0.71% of its stake after which the total value it holdings stand at $30,056,239, while The Vanguard Group, Inc. added 1.72% of its stake to hold $24.86 million in the firm. Over the last quarter, D. E. Shaw & Co. LP purchased 4,794,841 shares of Sorrento Therapeutics Inc., while Geode Capital Management LLC bought -314,823 shares. At present, JPMorgan Asset Management is holding 3,069,313 shares valued at $5.03 million. Morgan Stanley & Co. LLC owned 2,976,716 shares of the company at the time of its most recent 13F filing, worth $4.88 million.
The most recent change occurred on October 07, 2019 when JMP Securities began covering the stock and recommended ‘”a Mkt outperform”‘ rating along with a $21 price target.